Heart valve drug shows promise in preventing brain and kidney damage

NCT ID NCT05145283

Completed Prevention Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called conestat alfa in 141 people undergoing a minimally invasive heart valve replacement (TAVI) for severe aortic stenosis. The goal was to see if the drug could reduce the risk of small strokes and kidney damage that can happen after the procedure. Participants received either the drug or a placebo, and brain MRIs were used to measure any new damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis heart valve disorder ischemia reperfusion injury acute kidney injury prevention target ischemic stroke prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE ACUTE RENAL INJURY

Contacts and locations

Locations

Stadtspital Triemli Zürich, Division of Cardiology

Zurich, 8063, Switzerland
University Hospital Basel, Division of Internal Medicine

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.